Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Andrew Cheng M.D., Ph.D.
Karyawan
69
Negara
US
ISIN
US00973Y1082
Pencatatan
0 Comments
Bagikan pendapatmu
FAQ
Berapa harga saham Akero Therapeutics hari ini?▼
Harga saat ini dari AKRO adalah $54.65 USD — naik sebesar +0.18% dalam 24 jam terakhir. Pantau kinerja harga saham Akero Therapeutics lebih dekat di grafik.
Apa simbol saham Akero Therapeutics?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham Akero Therapeutics diperdagangkan dengan simbol AKRO.
Apakah harga saham Akero Therapeutics sedang naik?▼
Saham AKRO naik sebesar +0% dibandingkan minggu sebelumnya, perubahan bulanan naik +0%, dan selama setahun terakhir Akero Therapeutics menunjukkan kenaikan +41.43%.
Berapa pendapatan Akero Therapeutics tahun lalu?▼
Pendapatan Akero Therapeutics tahun lalu berjumlah 0 USD.
Berapa pendapatan bersih Akero Therapeutics tahun lalu?▼
Pendapatan bersih AKRO untuk tahun lalu adalah -252.06M USD.
Berapa jumlah karyawan Akero Therapeutics?▼
Per April 01, 2026, perusahaan memiliki 69 karyawan.
Akero Therapeutics berada di sektor apa?▼
Akero Therapeutics beroperasi di sektor Health Care.